AMR Industry Alliance Progress Report, 2021 Member survey

Partager l'article
Crédit : Pixabay

Article published on AMR Industry Alliance

The AMR Industry Alliance’s Progress Report reflects on collective achievements from the life sciences industry to minimize the spread of antimicrobial resistance (AMR). Findings from the leading coalition of biotechnology, diagnostics, generic and large research-based pharmaceutical companies indicate continued focus and leadership from the life sciences sector. Industry is helping to shape a positive future outlook in the fight against AMR but continued cross-sector collaborations along with policy and regulatory changes toward a more sustainable marketplace are needed. The report’s findings represent collective results from across Alliance membership on their current AMR activities related to research and science, access, appropriate use, and manufacturing and the environment.  The report was conducted by RAND Europe.

Key findings include:

  • There is continued funding in AMR from Alliance members, but investment levels are at risk. Since the previous survey period (2019-2020), at least USD$1.8 billion have been invested annually. Nearly one-third of members reported that investment would decrease if market conditions did not improve.
  • Incentives for R&D in antibiotics are critical for future investment. Almost three-quarters of Alliance members said they would increase investment if market conditions improved, particularly through sufficient novel pull incentives. These reward successful development and will be imperative to ensure market viability and enable sustainable investment into AMR R&D.
  • An overwhelming majority of Alliance members are active in access and appropriate use activities. Four out of five (81%) surveyed companies reported being active in supporting access to AMR-relevant products and/or technologies. Implementation of appropriate use and stewardship activities were also reported as a major focus of companies, with 92% of R&D pharmaceutical companies, 89% of generics companies, and 80% of diagnostics companies having taken such actions.
  • There is growing commitment and action on responsible manufacturing. An increasing number of Alliance members involved in manufacturing antibiotics (85%) are assessing their sites against the Alliance’s Common Antibiotic Manufacturing Framework (CAMF), and 87% of products manufactured at Alliance members sites are meeting its science-based predicted no-effect concentrations (PNEC) targets.

The report is based on independent, quality assured research conducted by RAND Europe and funded by the AMR Industry Alliance.